Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I
Institute of Clinical Pharmacology, Klinikum Steglitz, Free University Berlin, Germany.
Cancer Res. 1993 Mar 1;53(5):1004-11.
Glutathione S-transferase class mu (GSTM1) is known to detoxify certain carcinogens or their activated metabolites. In a previous study using phenotyping methods, individuals genetically devoid of this enzyme activity were significantly overrepresented among lung cancer patients compared to controls, suggesting that this trait is a risk factor for lung cancer. Here, GST class mu status has been determined both pheno- and genotypically, i.e., (a) by ex vivo measurement of trans-stilbene oxide conjugation in lymphocytes, (b) by GSTM1 quantification in blood using an immunoassay, and (c) by the application of polymerase chain reaction to genomic DNA with characterization of an inactivating mutation responsible for the null allele and a G/C single base allelic variance corresponding to the polymorphism of GSTM1 isoenzymes mu and psi, respectively. One hundred seventeen lung cancer patients and 155 control patients were studied. The two groups were of German origin and were similar with respect to age, sex, smoking history, and catchment area. In about 97% of cases, the three methods of assigning activity type of GSTM1 gave corresponding results. By genotype, 55 of 117 lung cancer patients (47.0%) and 73 of 155 control patients (47.1%) were GSTM1 active. The control group was confirmed by analysis of GSTM1 genotype in 200 further, independently studied reference patients; 101 of them were GSTM1 active (50.5%). Thus, the hypothesis of heritable GSTM1 deficiency as a host factor predisposing to lung cancer proved inappropriate. Detailed analysis of subgroups with respect to smoking habits, age, and sex failed to reveal an impact of GST class mu genotype on lung cancer risk. Among the total of 272 patients studied, 36 individuals carried at least one psi allele; however, no unexpected frequency distribution was observed.
谷胱甘肽S-转移酶μ类(GSTM1)已知可使某些致癌物或其活化代谢产物解毒。在先前一项使用表型分析方法的研究中,与对照组相比,肺癌患者中基因上缺乏这种酶活性的个体明显过多,这表明该特征是肺癌的一个危险因素。在此,通过表型和基因型两种方式确定了GSTμ类状态,即:(a)通过体外测量淋巴细胞中反式氧化芪的结合情况;(b)通过免疫测定法对血液中的GSTM1进行定量;(c)对基因组DNA应用聚合酶链反应,并对导致无效等位基因的失活突变以及分别对应于GSTM1同工酶μ和ψ多态性的G/C单碱基等位基因变异进行表征。对117例肺癌患者和155例对照患者进行了研究。两组均为德国血统,在年龄、性别、吸烟史和集水区方面相似。在约97%的病例中,三种确定GSTM1活性类型的方法得出了相应结果。通过基因型分析,117例肺癌患者中有55例(47.0%)GSTM1呈活性,155例对照患者中有73例(47.1%)GSTM1呈活性。通过对另外200例独立研究的参考患者进行GSTM1基因型分析,对对照组进行了验证;其中101例GSTM1呈活性(50.5%)。因此,遗传性GSTM1缺乏作为易患肺癌的宿主因素这一假设被证明是不恰当的。对吸烟习惯、年龄和性别亚组的详细分析未能揭示GSTμ类基因型对肺癌风险的影响。在总共272例研究患者中,36人携带至少一个ψ等位基因;然而,未观察到意外的频率分布。